Kiniksa Pharmaceuticals, Ltd. (KNSA)
NASDAQ: KNSA · IEX Real-Time Price · USD
17.46
+0.02 (0.11%)
Apr 16, 2024, 4:00 PM EDT - Market closed

Kiniksa Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Revenue
270.26220.1838.5400000
Revenue Growth (YoY)
22.74%471.24%------
Cost of Revenue
33.4122.99.100000
Gross Profit
236.85197.2929.4400000
Selling, General & Admin
129.4397.9585.9545.3234.9621.569.046.56
Research & Development
76.165.4999.3112.0413586.656.3617.44
Other Operating Expenses
56.5224.070.8400000
Operating Expenses
262.05187.51186.08157.36169.96108.1665.424
Operating Income
-25.29.77-156.64-157.36-169.96-108.16-65.4-24
Other Expense / Income
-8.54-1.25-0.1-1.13-6.05-4.72-0.53-0.07
Pretax Income
-16.6511.03-156.54-156.23-163.91-103.44-64.87-23.94
Income Tax
-30.74-172.341.395.15-2.05-0.2100.04
Net Income
14.08183.36-157.92-161.38-161.87-103.23-64.87-23.97
Net Income Growth
-92.32%-------
Shares Outstanding (Basic)
70696962543020
Shares Outstanding (Diluted)
72706962543020
Shares Change
2.13%2.69%10.89%14.42%82.92%1532.68%591.55%-
EPS (Basic)
0.202.64-2.30-2.61-2.99-3.49-35.85-91.61
EPS (Diluted)
0.202.60-2.30-2.61-2.99-3.49-35.85-91.61
EPS Growth
-92.31%-------
Free Cash Flow
13.175.79-126.71-136.82-161.57-86.3-50.29-21.87
Free Cash Flow Per Share
0.190.08-1.85-2.21-2.99-2.92-27.79-83.57
Gross Margin
87.64%89.60%76.39%-----
Operating Margin
-9.32%4.44%-406.38%-----
Profit Margin
5.21%83.28%-409.72%-----
Free Cash Flow Margin
4.87%2.63%-328.75%-----
Effective Tax Rate
--1563.01%------
EBITDA
-11.2616.47-151.55-152.42-160.64-103.16-64.84-23.92
EBITDA Margin
-4.17%7.48%-393.19%-----
Depreciation & Amortization
5.45.444.993.813.280.290.030.02
EBIT
-16.6511.03-156.54-156.23-163.91-103.44-64.87-23.94
EBIT Margin
-6.16%5.01%-406.13%-----
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).